Table 2. Protocols of rhuIL-2 treatment.

Source	Tan et al. [28]	Johnson et al. [29]	Chu et al. [30]	Johnson et al. [18]
Year of publication	2017	2003	2003	1997
Intervention group
-Source	China	Canada	China	Canada
-Beginning time	After inclusion and allocation	After inclusion and allocation	After inclusion and allocation	After inclusion and allocation
-Delivery method	Subcutaneous injection	Intradermal injection	Intradermal injection	Intradermal injection
-Bolus dose	50 × 104 U/mL	225,000 IU	200,000 IU	DRG: 225,000 IU PRG: 450,000 IU
- Schedule	Once every other day for 30 days separately during months 1, 3, 5, and 7.	Twice daily during the first 30 days of anti-TB treatment	Once daily for 30 days, followed by 30 days 'rest', for two cycles.	DRG: Twice daily for 30 consecutive days PRG: Daily at 12-h intervals for 5 days, followed by 9 days 'rest', for three cycles.
-Therapy period	7 months	30 days	90 days	30 days
Control group	Background drug regimen (chemotherapy)	Standard short-course chemotherapy with sterile 5% dextrose	Standard chemotherapy	Standard chemotherapy with diluent

TB: tuberculosis; DRG: Daily rhuIL-2 groups; PRG: Pulse-therapy rhuIL-2 group.